Avalglucosidase Alfa-Ngpt
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease.
Journal: Molecular genetics and metabolism
Published: June 03, 2024
Pompe disease: Unmet needs and emerging therapies.
Journal: Molecular genetics and metabolism
Published: May 09, 2024
Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa.
Journal: Frontiers in genetics
Published: October 07, 2023
Model-Informed Approach Supporting Approval of Nexviazyme (Avalglucosidase Alfa-ngpt) in Pediatric Patients with Late-Onset Pompe Disease.
Journal: The AAPS journal
Published: September 22, 2022
Regulatory news: Avalglucosidase alfa-ngpt (Nexviazyme) for late-onset Pompe disease-FDA approval summary.
Journal: Journal of inherited metabolic disease
Published: August 05, 2022
Avalglucosidase Alfa-ngpt.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: September 29, 2021
Showing 1-7 of 7
Last Updated: 04/28/2026